Company news
Shanghai Serum Bio-Technology Co., Ltd. news in 2024
Shanghai Serum Bio-Technology Co., Ltd.'s news releases, calls and decks from 2024, newest first.
Announcement on Provision for Impairment of Long-term Equity Investment
November 22, 2024
Report for Q3 2024
October 25, 2024
Announcement on Convening Q3 2024 Performance Briefing
October 21, 2024
Announcement on Resolution of the 1st Extraordinary General Meeting in 2024
September 30, 2024
Announcement on Convening 2024 Semi-annual Performance and Cash Dividend Briefing
September 18, 2024
Notice on Convening the 1st Extraordinary General Meeting in 2024
September 13, 2024
Announcement on Implementation of Dividend Distribution for Half Year of 2024
September 5, 2024
Announcement on the 2024 Semi-annual Profit Distribution Plan
August 27, 2024
Announcement on the Completion of the Implementation of the Shareholding Increase Plan for One of the Actual Controllers, Director, General Manager and Some Senior Executives and Results of Share Increase
August 15, 2024
Indicative Announcement on Postponing Term Change of Board of Directors and Board of Supervisors
August 5, 2024
Announcement on Receiving Proposals from the Chairman and One of the Actual Controllers to Implement the 2024 Interim Dividend and the "Corporate Value and Return Enhancement" Action Plan
July 16, 2024
Announcement on Implementation of Dividend Distribution of 2023
May 27, 2024
Announcement on Resolutions of 2023 Annual General Meeting
May 20, 2024
Announcement on Attending Biological Product Special Session of 2023 Annual Collective Performance Meeting and 2024 1st Quarter Performance Meeting
May 14, 2024
Announcement on Renewing Engagement of Audit Institution of 2024
April 26, 2024
Announcement on Progress in Shareholding Increase by One of Actual Controllers, Director, General Manager and Some Senior Management Members
March 6, 2024
Announcement on Circulation of Restricted Shares under Strategic Allotment in Initial Public Offering
March 1, 2024
Announcement on Shareholding Increase Plan of One of Actual Controllers, Director, General Manager and Some Senior Management Members
February 23, 2024
Announcement on Voluntary Disclosure of Ethical Review Approval for Phase II Clinical Trial of Antivenom Serum against Viper Venom
January 16, 2024